SEC Form 4 · accession 0001104659-17-006443
Ra Pharmaceuticals, Inc. · RARX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas A Treco
Officer — President & CEO · Director
Period of report
Feb 1, 2017
Accepted (ET)
Feb 3, 2017 · 4:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001481512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $16.64 | Feb 1, 2017 | A | 225,000 | A | — | Feb 1, 2027 | Common Stock | 225,000 | 225,000 | D |
Explanation of responses
- F1These stock options vest in 48 equal monthly installments at the end of each month following February 1, 2017, the grant date.